BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

1. (currently amended) ~~Bicyclic heterocycles~~ A quinazoline compound of ~~general~~ formula



, (I)

wherein

R_a denotes a hydrogen atom or a C_{1-4}-alkyl group,

R_b denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R_1 to R_3, whilst

R_1 and R_2, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine, bromine or iodine atom,

a C_{1-4}-alkyl, hydroxy, C_{1-4}-alkoxy, C_{3-6}-cycloalkyl, C_{4-6}-cycloalkoxy, C_{2-5}-alkenyl or C_{2-5}-alkynyl group,

an aryl, aryloxy, arylmethyl or arylmethoxy group,

a C_{3-5}-alkenyloxy or C_{3-5}-alkynyloxy group, whilst the unsaturated moiety may not be linked to the oxygen atom,

a C_{1-4}-alkylsulfenyl, C_{1-4}-alkylsulfinyl, C_{1-4}-alkylsulfonyl, C_{1-4}-alkylsulfonyloxy, trifluoromethylsulfenyl, trifluoromethylsulfinyl or trifluoromethylsulfonyl group,

a methyl or methoxy group substituted by 1 to 3 fluorine atoms,

an ethyl or ethoxy group substituted by 1 to 5 fluorine atoms,

a cyano or nitro group or an amino group optionally substituted by one or two C_{1-4}-alkyl groups, wherein the substituents may be identical or different, or

R_1 together with R_2, if they are bound to adjacent carbon atoms, denote a -CH=CH-CH=CH~~, -CH=CH-NH or -CH=N-NH~~ group and

R_3 denotes a hydrogen, fluorine, chlorine or bromine atom,

a C_{1-4}-alkyl, trifluoromethyl or C_{1-4}-alkoxy group,

X denotes ~~a methine group substituted by a cyano group or~~ a nitrogen atom,

A denotes an imino group optionally substituted by a C_{1-4}-alkyl group,

B denotes a carbonyl ~~or sulfonyl~~ group,

C denotes a 1,3-allenylene, 1,1- or 1,2-vinylene group which may be substituted in each case by one or two methyl groups or by a trifluoromethyl group,

an ethynylene group or

a 1,3-butadien-1,4-ylene group optionally substituted by 1 to 4 methyl groups or by a trifluoromethyl group,

D denotes an alkylene~~, -CO-alkylene or -SO_2-alkylene~~ group wherein the alkylene moiety ~~in each case~~ contains 1 to 8 carbon atoms and additionally 1 to 4 hydrogen atoms in the alkylene moiety may be replaced by fluorine atoms, ~~whilst the linking of the -CO-alkylene or -SO_2-alkylene group to the adjacent group C in each case must take place via the carbonyl or sulfonyl group,~~

~~a -CO-O-alkylene, -CO-NR$_4$-alkylene or -SO$_2$-NR$_4$-alkylene group wherein the alkylene moiety in each case contains 1 to 8 carbon atoms, whilst the linking to the adjacent group C in each case must take place via the carbonyl or sulfonyl group, wherein~~

~~R$_4$ denotes a hydrogen atom or a C$_{1-4}$-alkyl group,~~

~~or, if D is bound to a carbon atom of the group E, it may also denote a bond~~

~~or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl or sulfonyl group,~~

E denotes an amino, C$_{1-4}$-alkylamino or di-(C$_{1-4}$-alkyl)-amino group wherein the alkyl moieties may be identical or different,

a C$_{2-4}$-alkylamino group wherein the alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R$_5$, whilst

R$_5$ denotes a hydroxy, C$_{1-4}$-alkoxy, amino, C$_{1-4}$-alkylamino or di-(C$_{1-4}$-alkyl)-amino group,

~~a 4- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups or~~

~~a 6- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups wherein in each case a methylene group in position 4 is replaced by an oxygen or sulfur atom, by a sulfinyl, sulfonyl, imino or N-(C$_{1-4}$-alkyl)-imino group,~~

an N-(C$_{1-4}$-alkyl)-N-(C$_{2-4}$-alkyl)-amino group wherein the C$_{2-4}$-alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R$_5$, whilst R$_5$ is as hereinbefore defined,

a di-(C_{2-4}-alkyl)-amino group wherein the two C_{2-4}-alkyl moieties are substituted in each case in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R_5, whilst the substituents may be identical or different and R_5 is as hereinbefore defined,

a C_{3-7}-cycloalkylamino or C_{3-7}-cycloalkyl-C_{1-3}-alkylamino group wherein in each case the nitrogen atom may be substituted by a further C_{1-4}-alkyl group,

~~an amino or C_{1-4}-alkylamino group wherein in each case the nitrogen atom is substituted by a tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, 1-(tetrahydrofuran-3-yl)-piperidin-4-yl, 1-(tetrahydropyran-3-yl)-piperidin-4-yl, 1-(tetrahydropyran-4-yl)-piperidin-4-yl, 3-pyrrolidinyl, 3-piperidinyl, 4-piperidinyl, 3-hexahydro-azepinyl or 4-hexahydro-azepinyl group optionally substituted by 1 to 3 C_{1-4}-alkyl groups,~~

~~a 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 C_{1-2}-alkyl groups, which may be substituted by the group R_5 either at a cyclic carbon atom or at one of the alkyl groups, whilst R_5 is as hereinbefore defined,~~

~~a piperidino group substituted by a tetrahydrofuranyl, tetrahydropyranyl or tetrahydrofuranylmethyl group,~~

~~a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 C_{1-2}-alkyl groups wherein a methylene group in each case is replaced in the 4-position by an oxygen or sulfur atom, by an imino group substituted by the group R_6, or by a sulfinyl or sulfonyl group, whilst~~

~~R_6 denotes a hydrogen atom, a C_{1-4}-alkyl, 2-methoxy-ethyl, 3-methoxy-propyl, C_{3-7}-cycloalkyl, C_{3-7}-cycloalkyl-C_{1-4}-alkyl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, formyl, C_{1-4}-alkylcarbonyl, C_{1-4}-alkylsulfonyl, aminocarbonyl, C_{1-4}-alkylaminocarbonyl or di-(C_{1-4}-alkyl)-aminocarbonyl group,~~

~~an imidazolyl group optionally substituted by 1 to 3 methyl groups,~~

~~a C_{5-7}-cycloalkyl group wherein a methylene group is replaced by an oxygen or sulfur atom, by an imino group substituted by the group R_6, by a sulfinyl or sulfonyl group, whilst R_6 is as hereinbefore defined,~~

~~or D together with E denotes a hydrogen, fluorine or chlorine atom,~~

~~a C_{1-4}-alkyl group optionally substituted by 1 to 5 fluorine atoms,~~

~~a C_{3-6}-cycloalkyl group,~~

~~an aryl, heteroaryl, C_{1-4}-alkylcarbonyl or arylcarbonyl group,~~

~~a carboxy, C_{1-4}-alkoxycarbonyl, aminocarbonyl, C_{1-4}-alkylaminocarbonyl or di-(C_{1-4}-alkyl)-aminocarbonyl group or~~

~~a carbonyl which is substituted by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group may be replaced in the 4 position by an oxygen or sulfur atom, by an imino group substituted by the group R_6, by a sulfinyl or sulfonyl group, whilst R_6 is as hereinbefore defined, and~~

R_c denotes a C_{4-7}-cycloalkoxy or C_{3-7}-cycloalkyl-C_{1-6}-alkoxy group wherein the cycloalkyl moiety in each case may be substituted by a C_{1-3}-alkyl, hydroxy, C_{1-4}-alkoxy, amino, C_{1-4}-alkylamino, di-(C_{1-4}-alkyl)-amino, ~~pyrrolidino, piperidino, morpholino, piperazino, N-(C_{1-2}-alkyl)-piperazino,~~ hydroxy-C_{1-2}-alkyl, C_{1-4}-alkoxy-C_{1-2}-alkyl, amino-C_{1-2}-alkyl, C_{1-4}-alkylamino-C_{1-2}-alkyl, or di-(C_{1-4}-alkyl)-amino-C_{1-2}-alkyl, ~~pyrrolidino-C_{1-2}-alkyl, piperidino-C_{1-2}-alkyl, morpholino-C_{1-2}-alkyl, piperazino-C_{1-2}-alkyl or N-(C_{1-2}-alkyl)-piperazino-C_{1-2}-alkyl~~ group, whilst the abovementioned monosubstituted cycloalkyl moieties may additionally be substituted by a C_{1-3}-alkyl group,

~~a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuranylmethoxy group,~~

~~an C_{2-4}-alkoxy group substituted in β-, γ-, or δ-position with regard to the oxygen atom by an azetidin-1-yl, 4-methyl-homopiperazino or 4-ethyl-homopiperazino group,~~

~~a 3-pyrrolidinyloxy, 2-pyrrolidinyl-C_{1-4}-alkyloxy, 3-pyrrolidinyl-C_{1-4}-alkyloxy, 3-piperidinyloxy, 4-piperidinyloxy, 2-piperidinyl-C_{1-4}-alkyloxy, 3-piperidinyl-C_{1-4}-alkyloxy, 4-piperidinyl-C_{1-4}-alkyloxy, 3-hexahydro-azepinyloxy, 4-hexahydro-azepinyloxy, 2-hexahydro-azepinyl-C_{1-4}-alkyloxy, 3-He xahydro-azepinyl-C_{1-4}-alkyloxy or 4-hexahydro-azepinyl-C_{1-4}-alkyloxy group wherein in each case the cyclic nitrogen atom is substituted by the group R_6, where R_6 is as hereinbefore defined,~~ whilst

by the aryl moieties mentioned in the definition of the abovementioned groups is meant a phenyl group which in each case may be monosubstituted by R_7, mono-, di- or trisubstituted by R_8 or monosubstituted by R_7 and additionally mono- or disubstituted by R_8, wherein the substituents may be identical or different and

R_7 denotes a cyano, carboxy, C_{1-4}-alkoxycarbonyl, aminocarbonyl, C_{1-4}-alkylaminocarbonyl, di-(C_{1-4}-alkyl)-aminocarbonyl, C_{1-4}-alkylsulfenyl, C_{1-4}-alkylsulfinyl, C_{1-4}-alkylsulfonyl, hydroxy, C_{1-4}-alkylsulfonyloxy, trifluoromethyloxy, nitro, amino, C_{1-4}-alkylamino, di-(C_{1-4}-alkyl)-amino, C_{1-4}-alkylcarbonylamino, N-(C_{1-4}-alkyl)-C_{1-4}-alkylcarbonylamino, C_{1-4}-alkylsulfonylamino, N-(C_{1-4}-alkyl)-C_{1-4}-alkylsulfonylamino, aminosulfonyl, C_{1-4}-alkylaminosulfonyl or di-(C_{1-4}-alkyl)-aminosulfonyl group ~~or a carbonyl group which is substituted by a 5- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulfur atom, by a sulfinyl, sulfonyl, imino or N-(C_{1-4}-alkyl) imino group~~, and

R_8 denotes a fluorine, chlorine, bromine or iodine atom, a C_{1-4}-alkyl, trifluoromethyl or C_{1-4}-alkoxy group or

two groups R_8, if they are bound to adjacent carbon atoms, together denote a C_{3-5}-alkylene, ~~methylenedioxy~~ or 1,3-butadien-1,4-ylene group,

~~and the heteroaryl groups mentioned in the definition of the abovementioned groups include a 5-membered heteroaromatic group which contains an imino group, an oxygen or sulfur atom or an imino group, an oxygen or sulfur atom and one or two nitrogen atoms, or~~

~~a 6-membered heteroaromatic group which contains one, two or three nitrogen atoms,~~

~~whilst the abovementioned 5-membered heteroaromatic groups may be substituted in each case by 1 or 2 methyl or ethyl groups and the abovementioned 6-membered heteroaromatic groups may be substituted in each case by 1 or 2 methyl or ethyl groups or by a fluorine, chlorine, bromine or iodine atom or by a trifluoromethyl, hydroxy, methoxy or ethoxy group,~~

or the tautomers, or stereoisomers ~~and~~ or pharmaceutically acceptable salts thereof.

2. (currently amended) ~~Bicyclic heterocycles~~ A quinazoline of ~~general~~ formula I according to claim 1, wherein

R_a denotes a hydrogen atom,

R_b denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R_1 to R_3, whilst

R_1 and R_2, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine, bromine or iodine atom,

a C_{1-4}-alkyl, hydroxy, C_{1-4}-alkoxy, C_{3-6}-cycloalkyl, C_{4-6}-cycloalkoxy, C_{2-5}-alkenyl or C_{2-5}-alkynyl group,

an aryl, aryloxy, arylmethyl or arylmethoxy group,

a methyl or methoxy group substituted by 1 to 3 fluorine atoms,

a cyano or nitro group and

R_3 denotes a hydrogen, fluorine, chlorine or bromine atom,

a C_{1-4}-alkyl, trifluoromethyl or C_{1-4}-alkoxy group,

X denotes ~~a methine group substituted by a cyano group or~~ a nitrogen atom,

A denotes an imino group,

B denotes a carbonyl ~~or sulfonyl~~ group,

C denotes a 1,3-allenylene, 1,1- or 1,2-vinylene group,

an ethynylene or 1,3-butadien-1,4-ylene group,

D denotes an alkylene~~, -CO-alkylene or -SO_2-alkylene~~ group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms and additionally 1 to 4 hydrogen atoms in the alkylene moiety may be replaced by fluorine atoms, ~~whilst the linking of the -CO-alkylene or -SO_2-alkylene group to the adjacent group C in each case must take place via the carbonyl or sulfonyl group,~~

~~a -CO-O-alkylene, -CO-NR_4-alkylene or -SO_2-NR_4-alkylene group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms, whilst the linking to the adjacent group C in each case must take place via the carbonyl or sulfonyl group, wherein~~

~~R_4 denotes a hydrogen atom or a C_{1-4}-alkyl group,~~

~~or, if D is bound to a carbon atom of the group E, it may also denote a bond,~~

~~or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl or sulfonyl group,~~

E denotes a di-(C_{1-4}-alkyl)-amino group wherein the alkyl moieties may be identical or different,

an N-(C_{1-4}-alkyl)-N-(C_{2-4}-alkyl)-amino group wherein the C_{2-4}-alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R_5, where

R_5 denotes a hydroxy, C_{1-4}-alkoxy or di-(C_{1-4}-alkyl)-amino group,

~~a 4- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups or~~

~~a 6- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups wherein in each case a methylene group in position 4 is replaced by an oxygen or sulfur atom, or by a sulfinyl, sulfonyl or N-(C_{1-4}-alkyl)-imino group,~~

a di-(C_{2-4}-alkyl)-amino group wherein the two C_{2-4}-alkyl moieties in each case are substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R_5, wherein the substituents may be identical or different and R_5 is as hereinbefore defined,

a C_{3-7}-cycloalkylamino or C_{3-7}-cycloalkyl-C_{1-3}-alkylamino group wherein in each case the nitrogen atom is substituted by a further C_{1-4}-alkyl group,

~~a C_{1-4}-alkylamino group wherein the nitrogen atom is substituted by a tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, 1-(tetrahydrofuran-3-yl)-piperidin-4-yl, 1-(tetrahydropyran-3-yl)-piperidin-4-yl, 1-(tetrahydropyran-4-yl)-piperidin-4-yl, N-(C_{1-2}-alkyl)-3-pyrrolidinyl, N-(C_{1-2}-alkyl)-3-piperidinyl, N-(C_{1-2}-alkyl)-4-piperidinyl, N-(C_{1-2}-alkyl)-3-hexahydro-azepinyl or N-(C_{1-2}-alkyl)-4-hexahydro-azepinyl group,~~

~~an 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 methyl groups, which may be substituted either at a cyclic carbon atom or at one of the methyl groups by the group R_5, where R_5 is as hereinbefore defined,~~

~~a piperidino group substituted by a tetrahydrofuranyl, tetrahydropyranyl or tetrahydrofuranylmethyl group,~~

~~a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups wherein in each case a methylene group is replaced in the 4 position by an oxygen or sulfur atom, by an imino group substituted by the group R_6, by a sulfinyl or sulfonyl group, whilst~~

~~R_6 denotes a C_{1-4}-alkyl, 2-methoxy-ethyl, 3-methoxy-propyl, C_{3-7}-cycloalkyl, C_{3-7}-cycloalkyl-C_{1-4}-alkyl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, formyl, C_{1-4}-alkylcarbonyl, C_{1-4}-alkylsulfonyl, aminocarbonyl, C_{1-4}-alkylaminocarbonyl or di-(C_{1-4}-alkyl)-aminocarbonyl group,~~

~~a C_{5-7}-cycloalkyl group wherein a methylene group is replaced by an oxygen or sulfur atom, by an imino group substituted by the group R_6, or by a sulfinyl or sulfonyl group, where R_6 is as hereinbefore defined,~~

~~or D together with E denotes a hydrogen, fluorine or chlorine atom,~~

~~a C_{1-4}-alkyl group optionally substituted by 1 to 5 fluorine atoms,~~

~~a C_{3-6}-cycloalkyl group,~~

~~an aryl, C_{1-4}-alkylcarbonyl or arylcarbonyl group,~~

~~a carboxy, C_{1-4}-alkoxycarbonyl, aminocarbonyl, C_{1-4}-alkylaminocarbonyl or di-(C_{1-4}-alkyl)-aminocarbonyl group or~~

~~a carbonyl group which is substituted by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulfur atom, by an imino group substituted by the group R_6, or by a sulfinyl or sulfonyl group, where R_6 is as hereinbefore defined, and~~

R_c denotes a C_{4-7}-cycloalkoxy or C_{3-7}-cycloalkyl-C_{1-6}-alkoxy group wherein the cycloalkyl moiety in each case may be substituted by a C_{1-3}-alkyl, hydroxy, C_{1-4}-alkoxy, di-(C_{1-4}-alkyl)-amino, ~~pyrrolidino, piperidino, morpholino, N-(C_{1-2}-alkyl) piperazino,~~ hydroxy-C_{1-2}-alkyl, C_{1-4}-alkoxy-C_{1-2}-alkyl, or di-(C_{1-4}-alkyl)-amino-C_{1-2}-alkyl~~, pyrrolidino-C_{1-2}-alkyl, piperidino-~~

~~C_{1-2}-alkyl, morpholino-C_{1-2}-alkyl or N-(C_{1-2}-alkyl)-piperazino-C_{1-2}-alkyl~~ group, whilst the abovementioned monosubstituted cycloalkyl moieties may additionally be substituted by a C_{1-3}-alkyl group,

~~a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuranylmethoxy group,~~

~~an C_{2-4}-alkoxy group substituted in β-, γ-, or δ-position with regard to the oxygen atom by an azetidin-1-yl, 4-methyl-homopiperazino or 4-ethyl-homopiperazino group,~~

~~a 3-pyrrolidinyloxy, 2-pyrrolidinyl-C_{1-4}-alkyloxy, 3-pyrrolidinyl-C_{1-4}-alkyloxy, 3-piperidinyloxy, 4-piperidinyloxy, 2-piperidinyl-C_{1-4}-alkyloxy, 3-piperidinyl-C_{1-4}-alkyloxy, 4-piperidinyl-C_{1-4}-alkyloxy, 3-hexahydro-azepinyloxy, 4-hexahydro-azepinyloxy, 2-hexahydro-azepinyl-C_{1-4}-alkyloxy, 3-hexahydro-azepinyl-C_{1-4}-alkyloxy or 4-hexahydro-azepinyl-C_{1-4}-alkyloxy group wherein in each case the cyclic nitrogen atom is substituted by the group R_6, where R_6 is as hereinbefore defined~~, whilst

by the aryl moieties mentioned in the definition of the abovementioned groups is meant a phenyl group which may in each case be monosubstituted by R_7, mono-, di- or trisubstituted by R_8 or monosubstituted by R_7 and additionally mono- or disubstituted by R_8, wherein the substituents may be identical or different and

R_7 denotes a cyano, carboxy, C_{1-4}-alkoxycarbonyl, aminocarbonyl, C_{1-4}-alkylaminocarbonyl, di-(C_{1-4}-alkyl)-aminocarbonyl, C_{1-4}-alkylsulfenyl, C_{1-4}-alkylsulfinyl, C_{1-4}-alkylsulfonyl, hydroxy, C_{1-4}-alkylsulfonyloxy, trifluoromethyloxy, nitro, amino, C_{1-4}-alkylamino, di-(C_{1-4}-alkyl)-amino, C_{1-4}-alkylcarbonylamino, N-(C_{1-4}-alkyl)-C_{1-4}-alkylcarbonylamino, C_{1-4}-alkylsulfonylamino, N-(C_{1-4}-alkyl)-C_{1-4}-alkylsulfonylamino, aminosulfonyl, C_{1-4}-alkylaminosulfonyl or di-(C_{1-4}-alkyl)-aminosulfonyl group ~~or a carbonyl group which is substituted by a 5- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group may be replaced in the 4-position by an oxygen or sulfur atom, by a sulfinyl, sulfonyl, imino or N-(C_{1-4}-alkyl)-imino group~~, and

R_8 denotes a fluorine, chlorine, bromine or iodine atom, a C_{1-4}-alkyl, trifluoromethyl or C_{1-4}-alkoxy group or

two groups R_8, if they are bound to adjacent carbon atoms, together denote a C_{3-5}-alkylene~~,~~ ~~methylenedioxy~~ or 1,3-butadien-1,4-ylene group,

or the tautomers, or stereoisomers ~~and~~ or pharmaceutically acceptable salts thereof.

3. (currently amended) ~~Bicyclic heterocycles~~ A quinazoline of ~~general~~ formula I according to claim 1, wherein

R_a denotes a hydrogen atom,

R_b denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R_1 and R_2, where

R_1 and R_2, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine or bromine atom,

a methyl, trifluoromethyl or methoxy group,

X denotes a nitrogen atom,

A denotes an imino group,

B denotes a carbonyl group,

C denotes a 1,2-vinylene group,

an ethynylene or 1,3-butadien-1,4-ylene group,

D denotes a C_{1-4}-alkylene group,

~~or, if D is bound to a carbon atom of the group E, it may also denote a bond,~~

~~or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl group,~~

E denotes a di-(C_{1-4}-alkyl)-amino group wherein the alkyl moieties may be identical or different,

an N-(C_{1-4}-alkyl)-N-(C_{2-4}-alkyl)-amino group wherein the C_{2-4}-alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R_5, whilst

R_5 denotes a hydroxy, C_{1-3}-alkoxy or di-(C_{1-3}-alkyl)-amino group,

~~a pyrrolidino, piperidino or morpholino group,~~

a di-(C_{2-4}-alkyl)-amino group wherein the two C_{2-4}-alkyl moieties in each case are substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R_5, wherein the substituents may be identical or different and R_5 is as hereinbefore defined,

~~an C_{1-4}-alkylamino group substituted at the nitrogen atom by a tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, 1-(C_{1-2}-alkyl)-pyrrolidin-3-yl, 1-(C_{1-2}-alkyl) piperidin-3-yl, 1-(C_{1-2}-alkyl) piperidin-4-yl, 1-(tetrahydrofuran-3-yl)-piperidin-4-yl, 1-(tetrahydropyran-3-yl)-piperidin-4-yl or 1-(tetrahydropyran-4-yl)-piperidin-4-yl group,~~

a C_{3-5}-cycloalkylamino or C_{3-5}-cycloalkyl-C_{1-3}-alkylamino group wherein in each case the nitrogen atom is substituted by a further C_{1-3}-alkyl group,

~~a 5- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups which may be substituted either at a cyclic carbon atom or at one or the methyl groups by the group R_5, where R_5 is as hereinbefore defined, or~~

~~a piperidino group substituted by a tetrahydrofuranyl, tetrahydropyranyl or tetrahydrofuranylmethyl group,~~

~~a piperidino group optionally substituted by 1 or 2 methyl groups wherein the methylene group is replaced in the 4 position by an oxygen or sulfur atom, by sulfinyl or sulfonyl group or by an imino group substituted by the group R_6, whilst~~

~~R_6 denotes a C_{1-3}-alkyl, 2-methoxy-ethyl, 3-methoxy-propyl, C_{3-6}-cycloalkyl, C_{3-6}-cycloalkyl-C_{1-3}-alkyl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, C_{1-3}-alkylcarbonyl, C_{1-3}-alkylsulfonyl, aminocarbonyl, C_{1-3}-alkylaminocarbonyl or di-(C_{1-3}-alkyl)-aminocarbonyl group,~~

~~or D together with E denotes a hydrogen atom,~~

~~a C_{1-3}-alkyl group,~~

~~an aryl or C_{1-4}-alkylcarbonyl group or~~

~~a C_{1-4}-alkoxycarbonyl group,~~

R_c denotes a C_{4-7}-cycloalkoxy or C_{3-7}-cycloalkyl-C_{1-4}-alkoxy group wherein the cycloalkyl moiety in each case may be substituted by a C_{1-3}-alkyl or C_{1-3}-alkoxy group,

~~a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuranylmethoxy group,~~

~~an C_{2-4}-alkoxy group substituted in β-, γ-, or δ-position with regard to the oxygen atom by an azetidin-1-yl, 4-methyl-homopiperazino or 4-ethyl-homopiperazino group,~~

~~a 3-pyrrolidinyloxy, 2-pyrrolidinyl-C_{1-3}-alkyloxy, 3-pyrrolidinyl-C_{1-3}-alkyloxy, 3-piperidinyloxy, 4-piperidinyloxy, 2-piperidinyl-C_{1-3}-alkyloxy, 3-piperidinyl-C_{1-3}-alkyloxy, 4-piperidinyl-C_{1-3}-alkyloxy, 3-hexahydro-azepinyloxy, 4-hexahydro-azepinyloxy, 2-hexahydro-azepinyl-C_{1-3}-alkyloxy, 3-hexahydro-azepinyl-C_{1-3}-alkyloxy or 4-hexahydro-~~

~~azepinyl-C_{1-3}-alkyloxy group wherein in each case the cyclic nitrogen atom is substituted by a methyl or ethyl group, whilst~~

~~by the aryl moieties mentioned in the definition of the abovementioned groups is meant a phenyl group which may be mono-, di- or trisubstituted by R_8, wherein the substituents may be identical or different and~~

~~R_8 denotes a fluorine, chlorine, bromine or iodine atom, a C_{1-4}-alkyl, trifluoromethyl or C_{1-4}-alkoxy group,~~

or the tautomers, or stereoisomers ~~and~~ or pharmaceutically acceptable salts thereof.

4. (currently amended) ~~Bicyclic heterocycles~~ A quinazoline of ~~general~~ formula I according to claim 1, wherein

R_a denotes a hydrogen atom,

R_b denotes a phenyl, benzyl or 1-phenylethyl group, whilst the phenyl nucleus is substituted in each case by the radicals R_1 and R_2, whilst

R_1 and R_2, which may be identical or different, each denotes a hydrogen, fluorine, chlorine or bromine atom,

X denotes a nitrogen atom,

A denotes an imino group,

B denotes a carbonyl group,

C denotes a 1,2-vinylene, ~~ethinylene~~ethynylene or 1,3-butadien-1,4-ylene group,

D denotes an C_{1-3}-alkylene group,

E denotes a Di-(C_{1-4}-alkyl)-amino group, wherein the alkyl moieties may be identical or different,

a methylamino or ethylamino group each substituted at the nitrogen atom by a 2-methoxyethyl, 1-methoxy-2-propyl, 2-methoxypropyl, 3-methoxypropyl, ~~tetrahydrofuran-3-yl, tetrahydropyran-4-yl, tetrahydrofuran-2-ylmethyl, 1-methylpiperidin-4-yl, 1-ethyl-piperidin-4-yl, 1-(tetrahydrofuran-3-yl)-piperidin-4-yl,~~ cyclopropyl or cyclopropylmethyl group,

a ~~Bis~~bis-(2-methoxyethyl)amino group,

~~a pyrrolidino, piperidino or morpholino group each optionally substituted by one or two methyl groups,~~

~~a piperazino group substituted in 4-position by a methyl, ethyl, cyclopropyl, cyclopropylmethyl, 2-methoxy-ethyl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl or tetrahydrofuran-2-ylmethyl group,~~

~~a thiomorpholino, S-oxidothiomorpholino or S,S-dioxidothiomorpholino group,~~

~~a 2-(methoxymethyl)pyrrolidino, 2-(ethoxymethyl)pyrrolidino, 4-hydroxypiperidino, 4-methoxypiperidino, 4-ethoxypiperidino, 4-(tetrahydrofuran-3-yl)piperidino or 4-morpholinopiperidino group~~

~~or D together with E denote a hydrogen atom, a methyl, phenyl, methoxycarbonyl or ethoxycarbonyl group and~~

R_c denotes a cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy or cyclohexylmethoxy group,

a cyclobutyloxy, cyclopentyloxy or cyclohexyloxy group,

~~a tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuran-2-ylmethoxy group,~~

~~a straight-chained C_{2-4}-alkoxy group terminally substituted by an azetidin-1-yl, 4-methyl-homopiperazino or 4-ethyl-homopiperazino group,~~

~~a 1-methyl-piperidin-4-yloxy or 1-ethyl-piperidin-4-yloxy group,~~

~~a (1-methyl-piperidin-4-yl)-C_{1-3}-alkyloxy or (1-ethyl-piperidin-4-yl)-C_{1-3}-alkyloxy group,~~

or the tautomers, or stereoisomers ~~and~~ or pharmaceutically acceptable salts thereof.

5. (currently amended) ~~Bicyclic heterocycles~~ A quinazoline of ~~general~~ formula I according to claim 1, wherein

R_a denotes a hydrogen atom,

R_b denotes a 1-phenylethyl group or a phenyl group wherein the phenyl nucleus is substituted by the radicals R_1 and R_2, whilst

R_1 and R_2, which may be identical or different, each denote a hydrogen, fluorine, chlorine or bromine atom,

X denotes a nitrogen atom,

A denotes an imino group,

B denotes a carbonyl group,

C denotes a 1,2-vinylene, ~~ethinylene~~ ethynylene or 1,3-butadien-1,4-ylene group,

D denotes a methylene group,

E denotes a dimethylamino, diethylamino, Bis(2-methoxyethyl)amino, *N*-methyl-*N*-(2-methoxyethyl)amino, *N*-ethyl-*N*-(2-methoxyethyl)amino, *N*-methyl-*N*-cyclopropylamino, *N*-methyl-*N*-cyclopropylmethyl-amino, *N*-methyl-*N*-(1-methoxy-2-propyl)amino, *N*-methyl-

N-(2-methoxypropyl)amino~~,~~ or *N*-methyl-*N*-(3-methoxypropyl)amino, *N*-methyl-*N*-(tetrahydrofuran-3-yl)amino, *N*-methyl-*N*-(tetrahydropyran-4-yl)amino~~, *N*-methyl-*N*-(tetrahydrofuran-2-ylmethyl)amino or *N*-methyl-*N*-(1-methylpiperidin-4-yl)amino~~ group,

~~a pyrrolidino, piperidino or morpholino group each optionally substituted by one or two methyl groups,~~

~~a piperazino group substituted in 4-position by a methyl, ethyl, cyclopropylmethyl or 2-methoxyethyl group,~~

~~a S-oxidothiomorpholino group,~~

~~a 2-(methoxymethyl)pyrrolidino, 4-hydroxypiperidino or 4-methoxypiperidino group~~

~~or D together with E denote a hydrogen atom, a methyl, phenyl or ethoxycarbonyl group, and~~

R_c denotes a cyclopropylmethoxy, cyclobutyloxy or cyclopentyloxy group,

~~a tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuran-2-ylmethoxy group,~~

~~a straight chained C_{2-4}-alkoxy group terminally substituted by an azetidin-1-yl or 4-methylhomopiperazino group,~~

~~a 1-methyl-piperidin-4-yloxy group or~~

~~a (1-methylpiperidin-4-yl)-C_{1-3}-alkyloxy group,~~

or the tautomers, or stereoisomers ~~and~~ or pharmaceutically acceptable salts thereof.

6. (currently amended) The following compounds of general formula I according to claim 1:

~~(a) 4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]-6-[(vinylcarbonyl)amino]quinazoline,~~

~~(b)~~ 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(*N*,*N*-diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline ~~and~~

~~(c) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline~~

~~as well as the salts thereof~~or pharmaceutically acceptable salts thereof.

7. (currently amended) ~~Physiologically~~ Pharmaceutically acceptable salts of the compounds according to ~~at least~~ one of claims 1 to 6 with inorganic or organic acids or bases.

8. (currently amended) Pharmaceutical compositions containing a compound according to at least one of claims 1 to 6, ~~or a physiologically acceptable salt according to claim 7~~ optionally together with one or more inert carriers and/or diluents.

9. (currently amended) ~~Use of a compound according to at least one of claims 1 to 7 for preparing a pharmaceutical composition which is suitable for treating~~ A method for treating or preventing a disease comprising administering a pharmaceutical composition according to one of claims 1 to 6, wherein said disease is selected from the group consisting of: benign or malignant tumors, ~~for preventing and treating~~ diseases of the airways and lungs and ~~for treating~~ diseases of the gastrointestinal tract and the bile duct and gall bladder.

Claims 10-11 (canceled)

12. (new) Pharmaceutical compositions containing a physiologically acceptable salt according to claim 7, optionally together with one or more inert carriers and/or diluents.

13. (new) A method for treating or preventing a disease comprising administering a pharmaceutical composition according to claim 7, wherein said disease is selected from the group consisting of: benign or malignant tumors, diseases of the airways and lungs and diseases of the gastrointestinal tract and the bile duct and gall bladder.